In addition, other relevant therapies based on incretins, including GIP receptor (GIP-R) agonists, dual GLP-1R/GIPR agonists, GLP-1R/GIPR/Glucagon receptor (GCGR) triagonists, and oxyntomodulin (OXM), have been shown to improve outcomes of T2DM in a series of preclinical trials (55, 56). Here, GIPR is linked to type 2 diabetes mellitus.